---
input_text: 'Changing Landscape of Dravet Syndrome Management: An Overview. Dravet
  syndrome (DS), previously known as severe myoclonic epilepsy of infancy, is a severe
  developmental and epileptic encephalopathy caused by loss-of-function mutations
  in one copy of SCN1A (haploinsufficiency), located on chromosome 2q24, with decreased
  function of Nav1.1 sodium channels in GABAergic inhibitory interneurons. Pharmacoresistant
  seizures in DS start in the infancy in the form of hemiclonic febrile status epilepticus.
  Later, other intractable seizure types develop including myoclonic seizures. Early
  normal development in infancy evolves into moderate to severe intellectual impairment,
  motor impairment, behavioral abnormalities, and later a characteristic crouching
  gait. Clobazam, valproate, levetiracetam, topiramate, zonisamide, ketogenic diet,
  and vagus nerve stimulation had been shown to be effective, but even with polytherapy,
  only 10% of patients get adequate seizure control. The author provides a narrative
  review of the current treatment paradigm as well as recent advances in the management
  of DS based on a comprehensive literature review (MEDLINE using PubMed and OvidSP
  vendors with appropriate keywords to incorporate recent evidence), personal practice,
  and experience. In recent years, the treatment paradigm of DS is changing with the
  approval of pharmaceutical-grade cannabidiol oil and stiripentol. Another novel
  antiepileptic drug (AED), fenfluramine, had also shown excellent efficacy in phase
  3 studies of DS. However, these AEDs primarily control seizures without addressing
  the underlying pathogenesis and other important common comorbidities such as cognitive
  impairment, autistic behavior, neuropsychiatric abnormalities, and motor impairment
  including crouching gait. Several agents targeted for DS are in the developmental
  stage: TAK935, lorcaserin, clemizole, huperzine analog, ataluren, selective sodium
  channel modulators and activators, antisense oligonucleotide therapy, and adenoviral
  vector therapy. As DS is associated with a high risk of sudden unexpected death
  in epilepsy, seizure detection devices can be used in this population for testing
  and clinical validation of these devices.'
raw_completion_output: |-
  primary_disease: Dravet Syndrome (DS)

  medical_actions: Pharmacotherapy; Ketogenic diet; Vagus nerve stimulation; Pharmacoresistant seizure management; Seizure control; Narrative review; Comprehensive literature review; Approval of pharmaceutical-grade cannabidiol oil; Approval of stiripentol; Fenfluramine administration; Seizure detection device use; Approval of novel antiepileptic drugs; Testing and clinical validation of seizure detection devices

  symptoms: Pharmacoresistant seizures; Hemiclonic febrile status epilepticus; Myoclonic seizures; Intellectual impairment; Motor impairment; Behavioral abnormalities; Crouching gait

  chemicals: Clobazam; Valproate; Levetiracetam; Topiramate; Zonisamide; Cannabidiol oil; Stiripentol; Fenfluramine; TAK935; Lorcaserin; Clemizole; Huperzine analog; Ataluren

  action_annotation_relationships: Pharmacotherapy TREATS pharmacoresistant seizures IN Dravet Syndrome (DS); Pharmacotherapy (with Clobazam) TREATS myoclonic seizures IN Dravet Syndrome (DS); Pharmacotherapy (with Valproate) TREATS myoclonic seizures IN Dravet Syndrome (DS); Pharmacotherapy (with Levetiracetam) TREATS myoclonic seizures IN Dravet Syndrome (DS); Pharmacotherapy (with Topiramate) TREATS myoclonic seizures IN Dravet Syndrome (DS); Pharmacotherapy (with Zonisamide) TREATS myoclonic seizures IN Dravet Syndrome (DS); Ketogenic diet TREATS myoclonic seizures IN Dravet Syndrome (DS); Vagus nerve stimulation TREATS myoclonic seizures IN Dravet Syndrome (DS); Approval of pharmaceutical-grade cannabidiol oil TREATS pharmacoresistant seizures IN Dravet Syndrome (DS); Approval of stiripentol TREATS pharmacoresistant seizures IN Dravet Syndrome (DS); Fenfluramine administration TREATS pharmacoresistant seizures IN Dravet Syndrome (DS); Seizure detection device use PREVENTS sudden unexpected death IN Dravet Syndrome (DS)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Seizure detection device use PREVENTS sudden unexpected death IN Dravet Syndrome (DS)

  ===

extracted_object:
  primary_disease: MONDO:0100135
  medical_actions:
    - MAXO:0000058
    - Ketogenic diet
    - MAXO:0000942
    - Pharmacoresistant seizure management
    - Seizure control
    - Narrative review
    - Comprehensive literature review
    - Approval of pharmaceutical-grade cannabidiol oil
    - Approval of stiripentol
    - Fenfluramine administration
    - Seizure detection device use
    - Approval of novel antiepileptic drugs
    - Testing and clinical validation of seizure detection devices
  symptoms:
    - Pharmacoresistant seizures
    - Hemiclonic febrile status epilepticus
    - HP:0032794
    - HP:0100543
    - Motor impairment
    - HP:0000708
    - Crouching gait
  chemicals:
    - CHEBI:31413
    - CHEBI:60654
    - CHEBI:6437
    - CHEBI:63631
    - CHEBI:10127
    - Cannabidiol oil
    - CHEBI:228488
    - CHEBI:5000
    - TAK935
    - CHEBI:65353
    - CHEBI:52140
    - Huperzine analog
    - Ataluren
  action_annotation_relationships:
    - subject: MAXO:0000058
      predicate: TREATS
      object: pharmacoresistant seizures
      qualifier: MONDO:0100135
      subject_extension: Pharmacotherapy
    - subject: MAXO:0000058
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
      subject_qualifier: with Clobazam
      subject_extension: CHEBI:31413
    - subject: MAXO:0000058
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
      subject_qualifier: with Valproate
      subject_extension: CHEBI:60654
    - subject: MAXO:0000058
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
      subject_qualifier: with Levetiracetam
      subject_extension: CHEBI:6437
    - subject: MAXO:0000058
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
      subject_extension: CHEBI:63631
    - subject: MAXO:0000058
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
      subject_qualifier: with Zonisamide
      subject_extension: CHEBI:10127
    - subject: Ketogenic diet
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
      subject_extension: ketogenic diet
    - subject: MAXO:0000942
      predicate: TREATS
      object: HP:0032794
      qualifier: MONDO:0100135
    - subject: Approval
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: pharmaceutical-grade cannabidiol oil
      object_extension: pharmacoresistant
    - subject: Approval
      predicate: TREATS
      object: pharmacoresistant seizures
      qualifier: MONDO:0100135
      subject_extension: CHEBI:228488
    - subject: administration
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      object_qualifier: pharmacoresistant
      subject_extension: CHEBI:5000
      object_extension: pharmacoresistant
    - subject: Seizure detection device use
      predicate: PREVENTS
      object: sudden unexpected death
      qualifier: MONDO:0100135
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
  - id: HP:0012758
    label: Neurodevelopmental delays
  - id: HP:0011951
    label: Aspiration pneumonia
  - id: CHEBI:71013
    label: Perampanel
  - id: CHEBI:63004
    label: Sodium bromide
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0000718
    label: Aggression
  - id: HP:0031475
    label: nonconvulsive status epilepticus
  - id: HP:0001609
    label: hoarseness
  - id: HP:0000752
    label: hyperactivity
  - id: HP:0002446
    label: astrogliosis
  - id: CHEBI:9948
    label: verapamil
  - id: CHEBI:52140
    label: clemizole
  - id: CHEBI:3387
    label: Carbamazepine
  - id: CHEBI:40594
    label: AEDs
  - id: CHEBI:68478
    label: Everolimus
  - id: HP:6000040
    label: Neuropathic pain
  - id: CHEBI:65353
    label: lorcaserin
  - id: MAXO:0000016
    label: Cell therapies
  - id: HP:0001699
    label: Sudden death
  - id: CHEBI:59729
    label: Fenfluramine hydrochloride
  - id: HP:0030650
    label: focal
